1. Search Result
Search Result
Results for "

ATP hydrolysis

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108666
    ATPγS tetralithium salt
    1 Publications Verification

    Adenosine-5'-O-(3-thiotriphosphate) tetralithium salt; Adenosine 5'-[γ-thio]triphosphate tetralithium salt

    Eukaryotic Initiation Factor (eIF) P2Y Receptor Neurological Disease Metabolic Disease Inflammation/Immunology
    ATPγS (tetralithium salt) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATPγS (tetralithium salt) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATPγS (tetralithium salt) is active in ATP hydrolysis .
    ATPγS tetralithium salt
  • HY-77195

    Polo-like Kinase (PLK) Cancer
    Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive Plk1 inhibitor, with moderate Plk1 inhibitory activity.
    Poloxime
  • HY-160519

    Bacterial Antibiotic Infection
    Targocil-II (Compound 2) is an ABC transporter inhibitor with a IC50 value of 137 nM. Targocil-II prevents ATP hydrolysis by binding to allosteric sites of the TM domain. Targocil-II has (antibacterial) activity .
    Targocil-II
  • HY-112433A

    NF-κB Drug Isomer Inflammation/Immunology
    (S)-NIK SMI1 is the isomer of NIK SMI1 (HY-112433), and can be used as an experimental control. NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM.
    (S)-NIK SMI1
  • HY-134361

    P2Y Receptor Eukaryotic Initiation Factor (eIF) Neurological Disease Metabolic Disease Inflammation/Immunology
    ATP-γ-S (tetrasodium) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATP-γ-S (tetrasodium) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATP-γ-S (tetrasodium) is active in ATP hydrolysis .
    ATP-γ-S tetrasodium
  • HY-149736

    PKA ATP Synthase Cardiovascular Disease
    ATP Synthesis-IN-3 (compound 31) is an ATP hydrolysis inhibitor with protective effects during myocardial ischemia. ATP Synthesis-IN-3 can increase the ATP content of ischemic cardiomyocytes, increase the phosphorylation of PKA and phospholamban, and inhibit ischemia-induced apoptosis .
    ATP Synthesis-IN-3
  • HY-134290

    Topoisomerase Cancer
    8-Chloro-ATP, an ATP (HY-B2176) analog, is a topoisomerase II (Topo II) inhibitor. 8-Chloro-ATP inhibits DNA synthesis and induces DNA double-stranded breaks (DSBs). 8-Chloro-ATP inhibits Topo II-catalyzed ATP hydrolysis .
    8-Chloro-ATP
  • HY-134290A

    Topoisomerase Cancer
    8-Chloro-ATP tetrasodium, an ATP (HY-B2176) analog, is a topoisomerase II (Topo II) inhibitor. 8-Chloro-ATP tetrasodium inhibits DNA synthesis and induces DNA double-stranded breaks (DSBs). 8-Chloro-ATP tetrasodium inhibits Topo II-catalyzed ATP hydrolysis .
    8-Chloro-ATP tetrasodium
  • HY-153398

    Phosphodiesterase (PDE) Infection Cancer
    Enpp-1-IN-17 (example 274) is a potent ENPP1 inhibitor, with the inhibition constants (Ki values) toward cGAMP and ATP hydrolysis of 100 nM-1 μM and > 1 μM, respectively. The selectivity ratio for inhibition of cGAMP hydrolysis versus ATP hydrolysis is >6.4 .
    Enpp-1-IN-17
  • HY-E70095

    Others Others
    T4 UvsY Protein is an accessory protein for in vitro catalysis of strand exchange. T4 UvsY Protein enhances strand exchange by UvsX protein by interacting specifically with UvsX protein. UvsY protein enhances the rate of single-stranded-DNA-dependent ATP hydrolysis by UvsX protein .
    T4 UvsY Protein
  • HY-W715630

    Topoisomerase Cancer
    Salvicine is a DNA topoisomerase II inhibitor (IC50=3 μM). Salvicine increases the interaction between DNA and Topo II by interacting with the ATPase domain, inhibiting DNA degradation and ATP hydrolysis. Salvicine has anticancer activities, including inhibiting Topo II, causing DNA damage, overcoming multidrug resistance, and inhibiting tumor cell adhesion .
    Salvicine
  • HY-112433
    NIK SMI1
    Maximum Cited Publications
    6 Publications Verification

    NF-κB Inflammation/Immunology
    NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM. NIK SMI1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    NIK SMI1
  • HY-121802
    Dynarrestin
    2 Publications Verification

    Hedgehog Cancer
    Dynarrestin is a aminothiazole inhibitor of cytoplasmic dyneins 1 and 2. Dynarrestin rapidly and reversibly inhibits dynein 1-driven microtubule gliding in vitro plus a range of dynein 1- and 2-dependent processes in cells without affecting ATP hydrolysis and interfering with ciliogenesis. Dynarrestin suppresses hedgehog (Hh)-dependent proliferation of neuronal precursors and tumor cells .
    Dynarrestin
  • HY-158116

    RO7589831; VVD-133214

    DNA/RNA Synthesis Cancer
    VVD-214 is a synthetic lethal allosteric inhibitor of WRN helicase with an IC50 of 0.1316 µM. VVD-214 covalently binds to cysteine 727 of WRN and inhibits ATP hydrolysis and helicase activity. VVD-214 is potent in causing double-stranded DNA breaks, nuclear swelling, and cell death in high microsatellite instability (MSI) cancers .
    VVD-214
  • HY-169860

    BCRP Cancer
    BCRP-IN-2 has BCRP inhibitory activity and shows even greater inhibition of BCRP after activation by ultraviolet light. BCRP-IN-2 can be a valuable probe for studying the interactions of quinazolinamine derivatives with BCRP, as it stimulates ATP hydrolysis of the BCRP transport protein, increasing the accumulation of mitoxantrone (HY-13502) in H460/MX20 cells with BCRP overexpression .
    BCRP-IN-2
  • HY-P10856

    P-glycoprotein Cancer
    CPI1 is a potent and highly specific multidrug resistance protein 1 (MRP1) inhibitor. CPI1 inhibits MRP1 (Ki: 100 nM) with nanomolar potency but shows minimal inhibition of P-glycoprotein (Pgp). CPI1 and LTC4 compete to bind to the same site of MRP1, inhibiting ATP hydrolysis and substrate transport. CPI1 can be used to study drug delivery and chemotherapy resistance in cancer .
    CPI1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: